Overview

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).

Phase:

PHASE2

Details

Lead Sponsor:

Medical University of South Carolina

Treatments:

130-nm albumin-bound paclitaxel
Cisplatin
Fluorouracil
Gemcitabine
irinotecan sucrosofate
Leucovorin
Oxaliplatin